Hair Repigmentation Reported With Baricitinib in Canities Subita - Report - MDSpire

Hair Repigmentation Reported With Baricitinib in Canities Subita

A single case suggests a possible benefit, but confounding factors and the off-label setting temper the conclusions.

  • By

  • Andrea Surnit

  • June 15, 2026

  • 4 min

Share

Clinical Report: Hair Repigmentation Reported With Baricitinib in Canities Subita

Overview

This case report describes hair repigmentation and regrowth in a 60-year-old male patient with canities subita and alopecia areata following treatment with baricitinib.

Background

Canities subita, characterized by sudden hair whitening, lacks established treatment options.

Data Highlights

No numerical data or trial data were provided in the article.

Key Findings

  • A 60-year-old male with rheumatoid arthritis experienced sudden hair whitening and alopecia areata.
  • Baricitinib 4 mg/day was initiated after discontinuation of etanercept.
  • Signs of pigmented hair appeared 4 months post-initiation, with complete hair repopulation by 8 months.
  • The patient’s rheumatoid arthritis remained in clinical remission throughout the treatment.
  • No adverse events were reported during the treatment period.

Clinical Implications

Clinicians should consider the safety risks associated with Janus kinase inhibitors when evaluating treatment options.

Conclusion

This case report provides evidence for the use of baricitinib in canities subita.

Related Resources & Content

  1. Corbella-Bagot L, et al., International Journal of Trichology, 2023 -- Hair Repigmentation Reported With Baricitinib in Canities Subita
  2. Baricitinib Demonstrates Efficacy in Refractory Rheumatoid Arthritis
  3. conexiant — Baricitinib Mono vs Combo: 6-Year RA Data
  4. Dermatology and Therapy (Springer) — Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
  5. conexiant — Rare Skin Reaction Reported With Tirzepatide
  6. Baricitinib Demonstrates Efficacy in Refractory Rheumatoid Arthritis
  7. Overview | Baricitinib for treating severe alopecia areata | Guidance | NICE
  8. British Association of Dermatologists living guideline for managing people with alopecia areata 2025
  9. Japanese Dermatological Association's Clinical Practice Guidelines for Alopecia Areata 2024: A Complete English Translated Version - Ohyama - 2025 - The Journal of Dermatology - Wiley Online Library
  10. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial - PMC
  11. Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2 - PubMed
  12. Frontiers | Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
  13. Successful Treatment of Canities Subita with Baricitinib - PMC
  14. Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights - PMC
  15. International Journal of Trichology

Original Source(s)

Hair Repigmentation Reported With Baricitinib in Canities Subita

  • by Andrea Surnit

  • June 15, 2026

Related Content

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.